Answers are grounded in this paper and cite their sources.
Narrative review reveals how BMPR2 mutations and estrogen signaling interact to elevate pulmonary arterial hypertension risk, highlighting novel therapeutic targets.
Group 1 pulmonary hypertension (pulmonary arterial hypertension; PAH) is a rare disease characterized by remodeling of the small pulmonary arteries leading to progressive elevation of pulmonary vascular resistance, ultimately leading to right ventricular failure and death. Deleterious mutations in the serine-threonine receptor bone morphogenetic protein receptor 2 (BMPR2; a central mediator of bone morphogenetic protein (BMP) signaling) and female sex are known risk factors for the development of PAH in humans. In this narrative review, we explore the complex interplay between the BMP and estrogen signaling pathways, and the potentially synergistic mechanisms by which these signaling cascades increase the risk of developing PAH. A comprehensive understanding of these tangled pathways may reveal therapeutic targets to prevent or slow the progression of PAH.
No takes yet. Share an insight, caveat, or question.
Cirulis et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: